Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
about
Emerging Influenza Strains in the Last Two Decades: A Threat of a New Pandemic?Assaying the Potency of Influenza VaccinesH5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer modelA cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults.Extrapolating theoretical efficacy of inactivated influenza A/H5N1 virus vaccine from human immunogenicity studies.MF59 adjuvant: the best insurance against influenza strain diversity.New technologies for influenza vaccines.Preflucel®: a Vero-cell culture-derived trivalent influenza vaccine.Evaluations for in vitro correlates of immunogenicity of inactivated influenza a H5, H7 and H9 vaccines in humans.Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets.Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01.Vaccines and global health.Safety and Immunogenicity of Cell Culture-Derived A/H3N2 Variant Influenza Vaccines: A Phase I Randomized, Observer-Blind, Dose-Ranging Study.Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses.Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines.Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes.Delta inulin-derived adjuvants that elicit Th1 phenotype following vaccination reduces respiratory syncytial virus lung titers without a reduction in lung immunopathology.The future of cell culture-based influenza vaccine production.Immunomodulatory properties of vitamins, flavonoids and plant oils and their potential as vaccine adjuvants and delivery systems.Assessing the safety of influenza vaccination in specific populations: children and the elderly.A multi-criteria decision making approach to identify a vaccine formulation.Morphologically virus-like fullerenol nanoparticles act as the dual-functional nanoadjuvant for HIV-1 vaccine.Humoral and cell-mediated immune responses to H5N1 plant-made virus-like particle vaccine are differentially impacted by alum and GLA-SE adjuvants in a Phase 2 clinical trial.
P2860
Q26783481-E1C01307-6DAD-41BD-BA2D-040F127292CCQ26783499-2B5BD319-46E2-4B59-8F5B-F127A4DBBCE5Q28741304-39A5CDC6-EB13-424E-8634-F5C11D6254A3Q30210342-6BB93A73-1447-470E-9BCC-CAB778EB0F1CQ30388996-8F2EBD6E-B841-47B0-9972-9D9E50C7CBDDQ30402018-259A3EE6-4170-4189-8DF9-586EF0326F1DQ30411859-9E21D70C-0642-4B0A-88F6-BC3776872B5BQ30420569-71B9A003-3C42-4765-B868-A57C0C067A25Q30424758-5382E940-A6B3-4D3C-A4B1-A9B1F24AD0BBQ33396140-21755643-9F36-4FA9-87C5-1B345C9D8833Q33793770-C8283BFC-AC8E-4503-8E98-C6FEA09B7D0BQ35137116-6B0D42B1-47F2-4581-9779-8FE9844BD923Q35974403-100CAAEE-8F18-4759-8F1C-E80549418167Q36106655-27B99A40-2040-4781-AFB8-F64E4550C168Q36362230-C41BCCC5-E0FA-4510-82B4-7389D1CF640AQ36410040-3D57DE72-E59D-4418-8F94-7D1DD6A2BBABQ37197103-406CFF21-4775-44FF-B146-8F69D4EF77A2Q37919896-17C35E4F-B451-455F-B833-1B80B0F122BEQ37939970-87CF2B46-0E82-429E-A40C-5681BB5DD6E4Q38045920-DECC2B0B-56EE-4E52-AAB7-CF21FA55EAEDQ41534119-CE8990C9-5E55-46DC-9241-5E705AF22B01Q42275411-46611634-3D8A-489B-AA10-6796C8553034Q47547355-31D152B4-8196-4BE4-997E-E8762F80572A
P2860
Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Dose ranging of adjuvant and a ...... of a phase 1/2 clinical trial.
@ast
Dose ranging of adjuvant and a ...... of a phase 1/2 clinical trial.
@en
type
label
Dose ranging of adjuvant and a ...... of a phase 1/2 clinical trial.
@ast
Dose ranging of adjuvant and a ...... of a phase 1/2 clinical trial.
@en
prefLabel
Dose ranging of adjuvant and a ...... of a phase 1/2 clinical trial.
@ast
Dose ranging of adjuvant and a ...... of a phase 1/2 clinical trial.
@en
P2093
P1433
P1476
Dose ranging of adjuvant and a ...... of a phase 1/2 clinical trial.
@en
P2093
Anne Katrin Hilbert
Astrid Borkowski
Maria Lattanzi
Michaela Praus
Nicola Groth
Ted F Tsai
P304
P356
10.1016/J.VACCINE.2009.10.019
P407
P577
2009-10-14T00:00:00Z